Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
{{output}}
Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-tria... ...
